رونوشت 🔗
WEBVTT
00:00:05.839 --> 00:00:09.679
Hello and welcome to the Gynecologic Oncology Journals Podcast.
00:00:09.839 --> 00:00:16.559
I am David Gaffney, Professor of Radiation Oncology at the University of Utah and Huntsman Cancer Institute.
00:00:16.800 --> 00:00:19.679
I am also an associate editor of the journal.
00:00:19.839 --> 00:00:21.199
Today I'm joined by Drs.
00:00:21.359 --> 00:00:25.760
Brennan Swift and Lillian Gien, and I'll have them introduce themselves.
00:00:26.480 --> 00:00:28.239
Hi everyone, I'm Brenna Swift.
00:00:28.320 --> 00:00:36.399
I'm a gynecologic oncologist at the Odette Cancer Center and Sunnybrook Health Sciences Center and an assistant professor at the University of Toronto.
00:00:37.200 --> 00:00:38.960
And I'm Lillian Gian.
00:00:39.439 --> 00:00:47.679
I'm a professor and division head of gynecologic oncology at the University of Toronto and also at the Sunnybrook Odette Cancer Center.
00:00:48.159 --> 00:00:56.240
They are the authors of Management of Inguinal Lymph Nodes in Locally Advanced Surgically Unresectable Squamous Cell Carcinoma of the Vulva.
00:00:56.399 --> 00:00:57.920
We're also joined today by Dr.
00:00:58.000 --> 00:00:58.880
Scott Glazer.
00:00:59.119 --> 00:01:01.520
Scott, go ahead and introduce yourself, please.
00:01:02.320 --> 00:01:02.560
Sure.
00:01:02.640 --> 00:01:03.119
I'm Dr.
00:01:03.200 --> 00:01:03.600
Glazer.
00:01:03.759 --> 00:01:09.760
I'm a radiation oncologist at City of Hope in Los Angeles, and I specialize in gynecologic cancer.
00:01:10.239 --> 00:01:10.560
Dr.
00:01:10.640 --> 00:01:14.879
Glazer is the lead author of the accompanying editorial.
00:01:15.120 --> 00:01:20.319
Both of these articles are available at gynecologic oncology-online.net.
00:01:20.480 --> 00:01:21.840
Thank you for joining Drs.
00:01:22.079 --> 00:01:25.359
Brennan Swift, Lillian Guian, and Scott Glazer.
00:01:25.760 --> 00:01:27.680
Let's go ahead and dive in.
00:01:27.840 --> 00:01:28.079
Dr.
00:01:28.319 --> 00:01:29.760
Swift and Guyenne.
00:01:30.000 --> 00:01:40.239
As you point out in your article, there are no previous studies that have compared surgical groin assessment to definitive radiotherapy when the vulvar tumor is surgically unresectable.
00:01:40.400 --> 00:01:43.519
Your paper is very important and it fills this void.
00:01:43.760 --> 00:01:46.560
Please describe your findings for our audience.
00:01:47.120 --> 00:01:47.760
Thank you, Dr.
00:01:47.840 --> 00:01:48.799
Gaffney and Dr.
00:01:48.879 --> 00:01:52.959
Glazer, for highlighting our work and the opportunity to discuss together today.
00:01:53.280 --> 00:02:03.920
Direct comparisons are challenging due to the rarity of advanced vulvar cancer, the heterogeneity involving groin involvement, and patient comorbidities, which may also affect treatment decisions.
00:02:04.159 --> 00:02:12.960
Our study was a retrospective assessment of patients treated at two academic centers with surgically unresectable squamous cell carcinoma of the vulva.
00:02:13.199 --> 00:02:21.919
Patients were treated with curative intent, primary radiotherapy, with or without chemotherapy for vulva tumors greater than 4 centimeters in size.
00:02:22.159 --> 00:02:28.719
We assessed groin recurrence in patients undergoing groin surgery compared to primary radiotherapy to the groin.
00:02:29.280 --> 00:02:37.919
Of 476 patients treated with radiation for vulva cancer, 112 patients met our inclusion and exclusion criteria.
00:02:38.159 --> 00:02:53.680
Our median follow-up was 1.9 years, and complete clinical response, including the vulva and groin, was significantly higher at 80% in patients with surgical groin resection compared to patients treated with primary groin radiotherapy at 58.2%.
00:02:54.319 --> 00:03:08.080
15 patients or 13.4% of the entire cohort had a groin treatment failure, of which 13 of 15 patients were initially treated with primary groin radiotherapy without a surgical groin assessment.
00:03:08.400 --> 00:03:17.840
Of patients treated with primary groin radiation, 11.9% had persistent groin disease, and 7.5% had groin recurrence.
00:03:18.080 --> 00:03:27.439
4.5% of patients had isolated groin treatment failures defined as either persistent or recurrent disease in the groin without an evolva disease.
00:03:27.599 --> 00:03:43.120
We also found that patients who were treated with primary groin radiotherapy with a dose of 63 gray or higher had a lower rate of groin treatment failure at 13.6% compared to 19.4% in the entire primary radiotherapy cohort.
00:03:43.360 --> 00:03:56.080
In the patients treated with groin surgical assessment, there were two groin recurrences, and there were no patients with persistent disease in the groin at completion of treatment, and no cases with an isolated groin treatment failure.
00:03:56.319 --> 00:04:13.919
One patient did not receive adjuvant radiation therapy, as at her groin surgery, there was just one micromet measuring one millimeter in size, and the other patient with a groin recurrence in the surgical group received 51 gray to the right groin after having a macromet measuring six millimeters at surgery.
00:04:14.159 --> 00:04:21.040
She did not have radiation to the left groin as a full groin dissection was negative, but her recurrence was in the left groin.
00:04:21.279 --> 00:04:31.120
44% of patients in our surgical group did not receive groin radiation due to the surgical assessment, and 11% of patients received unilateral groin radiation.
00:04:31.360 --> 00:04:45.360
On our multivariable analysis, after adjusting for clinical and or radiologically abnormal lymph nodes at presentation, surgical groin resection was significantly associated with lower groin recurrence with a hazard ratio of 0.2.
00:04:45.680 --> 00:04:59.199
The three-year groin recurrence resurvival was significantly higher at 94.4% in patients with surgical groin resection compared to 79.2% in patients treated with primary radiation to the groin.
Load full transcript
00:04:59.360 --> 00:05:09.279
In conclusion, in locally advanced squamous cell carcinoma of the vulva, surgical groin management improves groin recurrence free survival compared to radiotherapy alone.
00:05:09.680 --> 00:05:11.120
Brennan, thank you very much.
00:05:11.360 --> 00:05:18.959
Scott, as a radiation oncologist, please provide your critical review of the contributions and shortcomings of Dr.
00:05:19.120 --> 00:05:21.279
Swift and Guillen's study.
00:05:22.079 --> 00:05:22.319
Sure.
00:05:22.399 --> 00:05:34.720
Well, I want to start by thanking the authors for contributing this important work and helping us expand our knowledge and improve outcomes for this, often either somewhat forgotten or difficult to treat at a minimum.
00:05:34.879 --> 00:05:41.360
Patient population, locally advanced vulvar cancer is one of the rarer things that we encounter as radiation oncologists.
00:05:41.439 --> 00:05:44.879
And outcomes remain suboptimal for this patient population.
00:05:44.959 --> 00:05:50.959
And I do think this work helps us to improve outcomes for our patients, which is of robust importance.
00:06:02.720 --> 00:06:08.720
First of all, I don't think we can overlook the fact that there was such a difference between the two groups of patients in this study.
00:06:08.800 --> 00:06:18.000
I mean, a hazard ratio of 0.2 indicates that the effect of the intervention, meaning the surgery, was quite profound.
00:06:18.240 --> 00:06:28.639
In the patients who had surgical resection of the groins, the recurrence-free survival compared to radiotherapy alone was 94% versus 79%.
00:06:29.360 --> 00:06:44.480
So that means if patients underwent any form of surgical resection, whether that was a debulking, a full lymph node dissection, or just a isolated sentinel lymph node biopsy, their rates of recurrence were only 6% versus people who had just radiation, the rates of recurrence were 21%.
00:06:45.439 --> 00:06:47.519
I'm sorry, that's recurrence-free survival.
00:06:48.160 --> 00:06:54.079
There was also a suggestion of a dose response, which we've seen in other studies of vulvar cancer.
00:06:54.319 --> 00:07:09.199
In this study, the authors used a cut point of 63 gray and found that there was a 13% risk of groin recurrence for those who were treated to above 63 gray, and 22% for those treated to a dose below 63 gray.
00:07:09.439 --> 00:07:15.920
It's also important to note that using surgery can also help tailor the radiation dose and fields.
00:07:16.000 --> 00:07:30.720
And in the groin dissection cohort, 44% underwent no groin radiation due to negative groins after surgery, while 11% received unilateral radiation, which could help further decrease morbidity if we're able to do less radiation.
00:07:30.959 --> 00:07:39.839
With that being said, a few of the things that I would be interested in having more clarity on or made interpretability a little bit more challenging.
00:07:40.160 --> 00:07:42.560
One important one is the imbalance between the groups.
00:07:42.639 --> 00:07:51.439
You know, we know it's always hard to compare a surgical cohort group and a non-surgical group retrospectively due to some issues with selection bias.
00:07:51.920 --> 00:07:57.680
The authors did comment and adjust for the rate of clinical node positivity.
00:07:58.079 --> 00:08:01.040
However, there were other imbalances that remain unadjusted for.
00:08:01.279 --> 00:08:14.319
And particularly, there was a lower proportion of stage four patients, mostly stage four due to pelvic lymph node involvement, but a lower rate of stage four patients in the surgical cohort group.
00:08:14.560 --> 00:08:22.639
And there was also differences in the radiotherapy dose with patients who received surgery also receiving higher doses of radiotherapy.
00:08:23.120 --> 00:08:28.240
I think a place where this is seen the most is within the response in the vulva itself.
00:08:28.399 --> 00:08:33.440
Remember, in the vulva itself, patients did not receive any surgical intervention.
00:08:33.600 --> 00:08:45.519
And if you look at the clinical complete response rates in the vulva, it was 80% for patients who had surgery to the groin and only 58% to patients who had radiotherapy alone with no surgery to the groin.
00:08:45.679 --> 00:08:56.879
So it's a 22% difference in vulvar response rates, meaning there must be some difference in either how advanced those tumors were or the radiotherapy dose and technique to those tumors.
00:08:57.200 --> 00:09:01.120
Additionally, there were some other unknown variables that may influence the results.
00:09:01.600 --> 00:09:08.879
It would be super helpful to know more about their molecular status, including P53 status, HPV status.
00:09:09.279 --> 00:09:16.960
And lastly, you know, it'd be helpful to know a little bit more about incorporation of advanced imaging, such as PET scans to help with patient selection.
00:09:17.440 --> 00:09:28.159
Those were some of the main things that I you know would point out as far as opportunities to kind of know more about this patient population and to better stratify who needs what therapies.
00:09:29.440 --> 00:09:31.120
Thank you very much, Scott.
00:09:31.360 --> 00:09:31.600
Dr.
00:09:31.759 --> 00:09:36.000
Swift and Guillen, patients were accrued over a 20-year span.
00:09:36.240 --> 00:09:44.080
Please describe the standard groin surgery at the initiation of the study and what the optimal groin surgery is currently.
00:09:45.039 --> 00:09:53.919
You're right that as vulva cancer is a rare tumor presentation, we did include a large time period at two institutions to increase our sample size.
00:09:54.240 --> 00:10:00.639
However, there has been advances both in radiotherapy and surgical treatment of vulva cancer during this time period.
00:10:00.879 --> 00:10:18.799
The most notable change in practice in groin surgery for early vulva tumors was a result of the GROINS V1 and GOG173 that have shown sentinel lymph node assessment to have a
much lower morbidity and be accurate and oncologically safe for vulva tumors that are up to four centimeters in size.
00:10:19.039 --> 00:10:25.200
However, the false negative rate increases with larger vulva tumors, which was shown in GOG173.
00:10:25.440 --> 00:10:30.960
So the standard of care for large vulva tumors does still remain full inquinophemoral lymphatonectomy.
00:10:31.200 --> 00:10:49.360
Similarly, there's been advances in radiotherapy technique, including the addition of platinum-based chemo radiation and intensity modulated radiation therapy that have facilitated administration of higher doses of radiation to both the primary tumor and the groins while minimizing radiotherapy side effects to normal tissue.
00:10:49.519 --> 00:11:09.919
Due to the morbidity with full inquinal femoral lymphatinectomy, recent studies by Steckling, Rickman, Rishi et al, and in our study have shown that patients treated with radiotherapy to doses above 60 to 66 gray, even with clinically positive nodes, have acceptable rates of groin recurrence without receiving prior full inquinal femoral lymphatonectomy.
00:11:10.240 --> 00:11:29.200
I think this highlights the importance of the consideration of radiation dose to the groin and size of lymph node metastases, similar to the findings, albeit for much smaller vulva tumors in groinz B2, where 50 gray of radiation to the groin without full groin dissection was adequate treatment for micromets, but not for macromets to the groin.
00:11:29.360 --> 00:11:38.879
So further study, I think, is warranted to assess definitive groin radiotherapy and using higher doses of radiation to compare these outcomes with uh surgical resection.
00:11:39.360 --> 00:11:40.720
Thank you very much, Brennan.
00:11:40.879 --> 00:11:46.000
Uh Scott, similarly, describe radiotherapy changes over the past 20 years.
00:11:46.480 --> 00:11:49.840
I think radiotherapy has come a long way in the last 20 years.
00:11:50.000 --> 00:11:57.120
The IMRT revolution occurred roughly at that time point, you know, 20 years ago to maybe 15 years ago.
00:11:57.440 --> 00:12:07.039
And even though we've been doing IMRT for about that amount of time, I think the quality of our IMRT and the specifics of it have improved considerably.
00:12:07.440 --> 00:12:17.440
Rather than doing simple fixed field IMRT, which is less conformal, we've mostly switched over to doing VMAT therapy, which stands for volume modulated arc therapy.
00:12:17.679 --> 00:12:23.120
It allows for more degrees of freedom, meaning more beam angles and more conformality of the dose.
00:12:23.519 --> 00:12:45.279
The creation calls have gotten more comfortable with the idea of doing simultaneous integrated boosts, meaning giving one dose to the entire region and a higher dose to specific areas within the treatment field, which again allows for greater conformality and lower doses to nearby organs at risk, which in turn allows you to increase the dose to specific targets.
00:12:45.759 --> 00:12:48.559
So take a groin lymph node.
00:12:48.720 --> 00:13:09.440
Um you want to treat the entirety of the groin to say 50 or 54 gray, you could give the involved lymph node somewhere in the upper 50s to low 60s at the same time, rather than having to do a sequential boost over more days, which increases the treatment duration and increases the low dose spread out to nearby organs.
00:13:09.759 --> 00:13:14.080
So there are advancements in the radiation techniques and technologies themselves.
00:13:14.399 --> 00:13:19.440
We also have gotten better at targeting tumors with the incorporation of PET scans.
00:13:31.360 --> 00:13:34.399
And PET scan has helped us a lot in terms of that.
00:13:34.879 --> 00:13:47.600
There's been publication of a few different guidelines over this time period to better get people on the same page as far as the best treatment patterns, which has allowed for further personalization of uh treatment patient to patient.
00:13:48.320 --> 00:13:49.759
And then I would echo what Dr.
00:13:49.840 --> 00:14:00.799
Swift said about uh incorporation of concurrent radiosensitizing chemotherapy, whether that is to splatin or potentially drumcytamine as well, as done on the recent GOG279 trial.
00:14:01.039 --> 00:14:03.200
I think that has further improved our outcomes.
00:14:04.639 --> 00:14:04.879
Great.
00:14:05.039 --> 00:14:05.840
Thank you, Scott.
00:14:06.080 --> 00:14:06.399
Dr.
00:14:06.559 --> 00:14:10.480
Swift and Guillen, HPV negative vulvar tumors do worse.
00:14:10.639 --> 00:14:12.879
There are many studies that describe this.
00:14:13.200 --> 00:14:18.799
Do you recommend altering your treatment for HPV-negative tumors such as wider margins, et cetera?
00:14:18.960 --> 00:14:20.080
Please elaborate.
00:14:20.639 --> 00:14:21.200
Sure.
00:14:21.440 --> 00:14:23.279
Thanks for asking that question.
00:14:23.519 --> 00:14:25.679
The data has changed over time.
00:14:25.919 --> 00:14:38.720
When we talk about margin status, I think, you know, the first study was back in 1990, demonstrating that we should have an eight millimeter margin after a wide local excision for a vulgar cancer.
00:14:38.960 --> 00:14:41.919
But that margin has been questioned over time.
00:14:42.080 --> 00:14:56.399
These are all retrospective studies that have been done that, you know, question whether we really do need eight millimeters as a margin, or whether it should be five millimeters, whether it should be three millimeters, or whether it should just be a negative margin.
00:14:56.799 --> 00:15:05.440
And with more recent data, we think that particularly those that are HPV independent, perhaps they do worse.
00:15:05.679 --> 00:15:13.200
In retrospective data, it has demonstrated that those patients tend to have a higher risk of recurrence.
00:15:13.440 --> 00:15:23.840
And so now with molecular characterization, you wonder maybe that question of margins has been so unclear because we've mixed all those tumors
together.
00:15:24.000 --> 00:15:37.600
And if we separate those tumors into HPV associated versus HPV independent and then treat the HPV independent more aggressively, whether that be wider margins or adjuvant treatment, would that make a difference?
00:15:37.840 --> 00:15:47.200
That is, it's obviously hypothesis generating, and we do need to study that, which is the basis for the upcoming Strive trial.
00:15:47.440 --> 00:15:51.840
Strive is stratification of excision for vulgar cancers.
00:15:52.000 --> 00:15:58.879
And that is a trial that's being led by a Canadian group in Vancouver and uh will be an international trial.
00:15:58.960 --> 00:16:05.279
It is opening in Canada and also in Australia and hopefully in the US in the future.
00:16:05.519 --> 00:16:08.639
That question has remained to be seen at this point.
00:16:08.879 --> 00:16:18.960
There is data that is hypothesis generating regarding HPV-independent tumors and the requirement for wider margins than HPV-associated tumors.
00:16:19.440 --> 00:16:20.399
Thanks, Lillian.
00:16:20.559 --> 00:16:21.840
Scott, same question.
00:16:22.000 --> 00:16:27.919
Do you have different approaches for HPV-negative tumors in the radiotherapeutic management of vulgar cancers?
00:16:28.399 --> 00:16:34.559
The current time, as far as the radiation dose and volumes go, the short answer is no, not too much changes.
00:16:34.639 --> 00:17:04.079
But as far as how to incorporate both surgery and radiotherapy, I think that I am a lot more mindful that the response rates for HPV negative tumors are not as good and therefore am more inclined to push for surgical intervention either on lymph nodes or to debulk maybe a primary tumor for HPV negative tumor than I would be for HPV positive tumor, with which our control rates with radiation I do think are quite a bit better.
00:17:04.799 --> 00:17:22.079
Maybe I would give a little bit higher radiation dose to uh an HPV negative tumor, especially if it's bulky in a grand lymph node or the primary, but it's not too big of a difference and it's not very systematic as far as you know how much extra to give an HPV negative tumor.
00:17:22.640 --> 00:17:23.680
Thanks, Scott.
00:17:23.920 --> 00:17:24.160
Dr.
00:17:24.319 --> 00:17:25.359
Swift and Gann.
00:17:25.599 --> 00:17:30.480
Fortunately, there was no detriment in outcome with delayed radiotherapy post-surgery.
00:17:30.640 --> 00:17:36.400
There was a median of 84 days to initiate after surgery versus 47 days for the primary surgery group.
00:17:36.640 --> 00:17:39.839
What is the optimal time to begin radiotherapy post-surgery?
00:17:40.000 --> 00:17:45.519
Also, morbidity occurred in a relatively high fraction of your patients, specifically 49%.
00:17:46.240 --> 00:17:50.960
What can be done in the modern era to decrease surgical groin morbidity?
00:17:52.000 --> 00:18:02.400
You do correctly identify that surgical morbidity was an important finding in our paper and really does highlight the importance of patient comorbidities when considering treatment options.
00:18:02.640 --> 00:18:08.240
There was a significantly longer time to start radiation to the vulvar tumor in the groin surgery group.
00:18:08.319 --> 00:18:19.359
And this is likely a combination of both logistical considerations to organize operative time for the groin assessment, but also the surgical complication rate was quite high at almost 50% of patients.
00:18:19.680 --> 00:18:32.000
The most common surgical complications that we observed in order of frequency were groin cellulitis, lymphedema, lymphocyst formation, wound breakdown, groin abscess, and groin hematoma.
00:18:32.160 --> 00:18:39.279
Similar to other areas of surgery, general surgical principles to decrease wound infection also apply to groin surgery.
00:18:39.359 --> 00:19:12.720
And these include things like preoperative bathing, preoperative antibiotics within 60 minutes of skin incision, avoiding hair removal, but if it is required to clip in the OR rather than shaving, application of chlorhexidine skin preparation rather than polvodone iodine, minimizing the size of the groin incision and closing the subcutaneous tissue in layers, as well as avoiding interoperative hypothermia with the use of active warming and optimizing perioperative glucose control of diabetic and high BMI patients are important for decreasing wound infection rates.
00:19:13.039 --> 00:19:32.559
More specific to inguinal femoral lymphatonectomy, the ERAS Society does strongly recommend placing drains in the groin incisions until the drainage is less than about 30 to 50 cc's in 24 hours, as two prospective studies have shown lower rates of lymphocyal formation and other complications when drains are removed within these parameters.
00:19:32.799 --> 00:19:39.839
In addition, preservation of the saphenous vein is thought to sometimes be associated with lower rates of lymphedema and wound dehiscence.
00:19:40.400 --> 00:19:46.319
There's no evidence to support prolonged prophylactic antibiotics in this population.
00:19:46.720 --> 00:20:02.160
But I think it's also important to consider that for patients who may have very high perioperative risk, or especially if patients with fixed or immobile groin nodes, that it would be more appropriate to consider primary groin chemoradiotherapy with the higher radiation doses that we've discussed.
00:20:02.319 --> 00:20:05.680
As this would be very important to avoid the risk of treatment delays.
00:20:05.839 --> 00:20:12.000
As ideally, we do want patients to be starting radiation around three weeks after surgery to allow for surgical healing.
00:20:12.480 --> 00:20:14.640
Renna, thank you for those practical points.
00:20:14.880 --> 00:20:20.720
Scott, figure two is really exceptional, and I would like to compliment the authors for providing this.
00:20:20.960 --> 00:20:24.880
Figure two shows tumor control as a function of dose and size of lymph node.
00:20:25.039 --> 00:20:30.160
Higher doses showed
increased control, particularly doses greater than 63 gray.
00:20:30.319 --> 00:20:39.200
Figure 2A also showed that for lymph nodes over three centimeters, local failure occurred in about 37% of patients, albeit these are small numbers.
00:20:39.440 --> 00:20:43.759
For larger lymph nodes, if possible, should resection be performed?
00:20:44.400 --> 00:20:45.680
Thanks for pointing that out, Dave.
00:20:45.759 --> 00:20:47.279
I think the answer is absolutely.
00:20:47.359 --> 00:20:57.599
And I think the important thing that we can all take home from this paper is that there is a cohort of patients for whom radiation alone is not sufficient treatment.
00:20:57.839 --> 00:21:04.079
And we need to do a better job of identifying who those patients are and make sure we get them to surgery.
00:21:04.319 --> 00:21:10.079
And you point out in this question, you know, the size of three centimeters being a good cutoff to be aware of.
00:21:10.240 --> 00:21:14.960
And in the previous question, the HPV negative patients, you know, a factor to be aware of.
00:21:15.200 --> 00:21:24.160
And the thing that I tried to make a point of in the editorial was you know, if it's a bulky lymph node and it's HPV negative, radiation alone probably is not going to cut it.
00:21:24.240 --> 00:21:36.240
And you can try to give higher doses, you know, ideally above 63, 64 gray, and maybe you can get the job done, but the probability of success is dropping quite considerably.
00:21:36.559 --> 00:21:46.880
At the same time, you know, with highlighting the morbidity of surgery, should we be operating in the groin on people with the HPV positive tumor that is clinically node negative?
00:21:46.960 --> 00:21:50.960
You know, I'd make the argument that maybe those people don't need surgical intervention to the groin.
00:21:51.359 --> 00:21:54.799
And then there's the group in between, and how do we manage those patients?
00:21:54.880 --> 00:22:07.359
You know, it probably is a individualized decision making process, but the Definitely this group that needs more than just radiation, and you've pointed out two of the important factors HPV negative and size over three centimeters.
00:22:08.240 --> 00:22:09.599
Great, thank you, Scott.
00:22:09.839 --> 00:22:10.160
Dr.
00:22:10.319 --> 00:22:13.359
Swift and Guyenne, Goins V2 was a landmark study.
00:22:13.519 --> 00:22:15.759
Could you briefly describe Goins V2?
00:22:16.319 --> 00:22:21.279
Do the findings of Goins V2 inform your study at all, albeit these were different populations.
00:22:21.519 --> 00:22:26.480
Also, for our listeners, could you please describe the schema and goals of Goines V3?
00:22:27.839 --> 00:22:29.359
Sure, I'd be happy to do that.
00:22:29.680 --> 00:22:37.359
For Groins V2, this was a phase two single-arm prospective observational study.
00:22:37.599 --> 00:22:50.559
So essentially it was asking the question: if you have metastases in the sentinel and lymph node, can you give radiation therapy to the groin instead of taking them back to the OR for a full groin node dissection?
00:22:50.720 --> 00:22:53.839
The dose of radiation to the groin was 50 grays.
00:22:54.000 --> 00:22:59.279
And the primary endpoint was to assess isolated groin recurrence within 24 months.
00:22:59.519 --> 00:23:11.599
Now, in this study, it was a landmark study in that there was 1,535 patients that were registered, amongst whom 21% had metastases in the groin.
00:23:11.759 --> 00:23:13.920
It was 322 patients.
00:23:14.240 --> 00:23:31.119
Now, when they were doing the study, there was an amendment that was done after 91 patients with positive centinal lymph nodes were included because they found that the isolated groin recurrence rate was exceeded, like the threshold was exceeded.
00:23:31.440 --> 00:23:41.200
And 10 patients had isolated groin recurrence, nine of whom had a metastases that was more than two millimeters or had extracapsular disease.
00:23:41.359 --> 00:23:49.839
So the amendment was such that they restricted the rest of the patients to having micromets only in order to have adjuvant radiation.
00:23:50.000 --> 00:23:54.079
Otherwise, those patients had to go back for a full groin node dissection.
00:23:54.480 --> 00:24:06.880
Once that was done, the patients who had the adjuvant groin radiation, for those who had less than two millimeter metastases or micromets in the sentinel lymph node, the groin recurrence rate was 1.6%.
00:24:07.519 --> 00:24:19.599
So basically, this demonstrated that for those with very small volume disease in the sentinel lymph node, less than two millimeters, that you could avoid doing a full groin node dissection.
00:24:20.079 --> 00:24:25.519
And there would be good groin control with adjuvant radiation at 50 grays.
00:24:26.000 --> 00:24:29.599
Now, groin's V3 is now the next step.
00:24:29.839 --> 00:24:36.480
What do we do for patients who have macromats or more than two millimeters in the sentinel lymph node?
00:24:36.720 --> 00:24:41.759
Can we still avoid doing a full groin node dissection if we alter the treatment?
00:24:42.000 --> 00:24:49.279
And so this Groin's V3 is also a prospective single arm observational study.
00:24:49.519 --> 00:24:59.359
Patients who have the sentinel lymph node done, I mean, obviously they need to have normal-looking nodes on their scans ahead of time in order to go through sentinel lymph node procedure.
00:24:59.599 --> 00:25:12.000
If you find that there's a macromet, these patients are now in this study being given 56 grays to the groin, so a boost to the groin, as well as concurrent chemotherapy along with their radiation.
00:25:12.079 --> 00:25:13.519
So adding in cisplatin.
00:25:13.680 --> 00:25:23.519
And can we be able to treat or control the groins adequately by boosting to 56 gray and also adding the concurrent chemo?
00:25:24.480 --> 00:25:24.799
Great.
00:25:24.880 --> 00:25:25.920
Thank you, Lillian.
00:25:26.319 --> 00:25:27.039
Scott, Dr.
00:25:27.200 --> 00:25:34.960
Horowitz recently published the NRG study of gem cytobine and cisplatin with increasing doses of radiotherapy utilizing IMRT.
00:25:35.200 --> 00:25:41.039
This study, together with previous historic GOG and NRG studies, showed a strong dose response.
00:25:41.200 --> 00:25:44.960
Please describe this important data for our audience.
00:25:45.440 --> 00:25:50.000
Thank you for the question about the recent GOG 279 trial.
00:25:50.160 --> 00:25:58.319
I'd like to just go back in time and uh discuss the evolution of the neoadjuvant regimen through a few of the prior GOG trials.
00:25:58.480 --> 00:26:09.440
So moving from GOG 101 to GOG 205, we increased the radiation dose by 20% and also uh removed 5FU from the treatment regimen.
00:26:09.599 --> 00:26:14.480
So GOG205 gave 57.6 gray along with concurrent cisplatin.
00:26:14.640 --> 00:26:21.920
And in that trial, the clinical complete response rate was 64%, and the pathologic complete response rate was 50%.
00:26:22.400 --> 00:26:32.960
In the recently published GOG279 trial, we increased the radiation dose further, up to 64 gray, and added in gem cytabine in addition to concurrent cisplatin.
00:26:33.119 --> 00:26:39.359
And in this trial, we showed that the pathologic complete response rate was further improved up to 71%.
00:26:40.240 --> 00:26:55.359
I would note that the true pathologic complete response rate may even be higher than that, as about 19% of patients for whom the protocol required a biopsy to confirm pathologic response did not undergo such a biopsy.
00:26:55.839 --> 00:27:03.440
So if all those patients had been pathologically negative, the true PCR rate could have been as high as 90% on GOG279.
00:27:03.759 --> 00:27:04.000
Great.
00:27:04.079 --> 00:27:04.880
Thank you, Scott.
00:27:05.039 --> 00:27:05.519
And Dr.
00:27:05.599 --> 00:27:09.440
Swift and Guinness vulvar cancer is a tough disease to treat.
00:27:09.599 --> 00:27:11.920
What changes do you see for the future?
00:27:12.400 --> 00:27:14.319
Thanks for asking that question.
00:27:14.559 --> 00:27:31.599
As we talked about before and alluded to before, perhaps there is a difference in the treatment of these cancers based on the molecular characterization of vulvar tumors, whether they're HPV associated or HPV-independent, P53 negative or positive.
00:27:32.000 --> 00:27:43.279
Another area for the future will be the continuation of the groin studies, specifically looking at sentinel lymph nodes and the treatments of metastatic disease.
00:27:43.440 --> 00:27:50.079
And the question will be: is there a role for full groin node dissection in the future with early stage vulvar cancer?
00:27:50.319 --> 00:27:59.119
Additionally, with the use of checkpoint inhibitors and cervix cancer, can we now apply that as well to patients with vulvar cancers?
00:27:59.279 --> 00:28:16.079
We do know that there has been a small phase two study of 100 patients with metastatic vulvar cancer in keynote 158 that did demonstrate an overall
response rate of approximately 11% with the use of pembrolisimab.
00:28:16.559 --> 00:28:23.759
Can we move this earlier in the treatment regimen and apply that to a locally advanced vulvar cancers?
00:28:23.920 --> 00:28:32.480
And if so, questions still remain about sequencing, whether this should be concurrent, whether this should be sequential.
00:28:32.720 --> 00:28:47.920
And then also for metastatic disease, you know, we know that we all have patients who have metastatic and recurrent vulvar cancer, and they do poorly because there really aren't that many options for these patients.
00:28:48.240 --> 00:28:55.759
Typically, we offer things like cisplatin and taxol based on what we have from cerveo cancer.
00:28:55.920 --> 00:29:04.640
We may add in bevisismab similarly, and then looking at immunotherapy, but really the options are few.
00:29:04.880 --> 00:29:17.920
And so there really should be a push for novel agents for patients with metastatic recurrent vulvar cancer to see if we can improve outcomes for these patients.
00:29:18.079 --> 00:29:19.359
And it is very difficult.
00:29:19.519 --> 00:29:21.039
This is a rare tumor.
00:29:21.279 --> 00:29:33.359
It requires investment from companies who are developing these novel therapeutics, which is difficult to do if it is a rare tumor and a small portion of the population.
00:29:33.759 --> 00:29:41.359
Also, you know, it's difficult to open studies when so few patients at each institution are enrolled.
00:29:41.519 --> 00:29:55.759
And so there needs to be, you know, with any of these studies, multi-institutional involvement and international collaboration and an investment in trying to find new therapies that will improve outcomes for these patients.
00:29:56.240 --> 00:29:57.200
Thank you, Lillian.
00:29:57.440 --> 00:29:57.920
Uh Dr.
00:29:58.000 --> 00:30:04.480
Glazer, similarly in radiotherapy, what is important for modern practice and what do you see for the future?
00:30:05.039 --> 00:30:11.599
Well, one of the most important things, I think, is to support the patients who are going through this sort of a treatment.
00:30:12.559 --> 00:30:21.279
You know, as a radiation oncologist, I think we often get a little bit either complacent or just used to seeing kind of what our patients have to go through.
00:30:21.519 --> 00:30:26.640
And I think in vulgar cancer, in particular, it's important to remember that this is a tough treatment on patients.
00:30:26.799 --> 00:30:31.359
You know, the incidence of toxicity is quite high and uh it can be quite profound.
00:30:31.519 --> 00:30:41.759
So, you know, compared to other disease sites for gynecologic radiation oncology, whether that's cervix or postopendometrial, you know, those patients typically do quite a bit better as far as toxicity goes.
00:30:41.920 --> 00:30:46.160
But in vulvar cancer patients really can have pretty profound toxicity.
00:30:46.240 --> 00:30:56.799
And having clear expectations with patients on what their treatment's going to be like and what they have to go through and helping them through that treatment, I think is very important for radiation oncologists to be aware of.
00:30:57.359 --> 00:31:01.119
I do think there's opportunity for further personalization, uh, as Dr.
00:31:01.359 --> 00:31:18.079
Gian mentioned, uh, whether that is using surgery to better tailor radiotherapy fields, incorporating more systemic therapy agents, whether that's checkpoint inhibitors or others, and not forgetting that the outcomes of these patients are not nearly as good as they should be.
00:31:18.319 --> 00:31:23.680
I think the three-year progression-free survival for patients with no cause of vulgar cancer is about 50%.
00:31:24.160 --> 00:31:28.079
So there's a lot of work to be done to make things better for these patients.
00:31:28.480 --> 00:31:28.799
Great.
00:31:28.960 --> 00:31:29.839
Thank you very much, Dr.
00:31:30.000 --> 00:31:30.640
Glazier.
00:31:30.720 --> 00:31:31.680
I would like to thank Dr.
00:31:31.920 --> 00:31:34.079
Swift, Gin, and Glazier.
00:31:34.319 --> 00:31:38.799
This was really a treat to participate in this podcast, and thank you to our audience.
00:31:39.039 --> 00:31:45.440
The article and the editorial we have discussed are available at gynecologic oncology online.net.
00:31:45.599 --> 00:31:51.759
And you can access our podcast at the journal's homepage, Apple iTunes, Google Play, and Spotify.
00:31:52.000 --> 00:31:53.920
Thank you very much for listening.